fonda, page-5

So far:

http://www.4-traders.com/DR-REDDY-S-LABORATORIES-9058869/news/Dr-Reddy-s-Laboratories-Limited-Dr-Reddy-s-Q3-9-months-FY13-Financial-Results-Q3-FY13-Revenue-16049971/

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Q3 & 9 months FY13 Financial Results: Q3 FY13 Revenues at Rs.28.7 billion (YoY growth of 23%); 9 months FY13 Revenues at Rs.82.9 billion (YoY growth of 26%)

02/14/2013| 04:55am US/Eastern

"Revenues from North America for Q3 FY13 at Rs.9.2 billion ($178 Mn), recorded YoY growth of 38%#.

Growth is largely driven by key limited competition products of ziprasidone, tacrolimus, fondaparinux and ramp-up in antibiotics portfolio."